

Supplementary

Table S1 Descriptive analysis of cell biomarkers

Variables	Description	N (%)
ALK	Yes	15 (10.7)
	No	77 (55.0)
	N/A	48 (34.3)
EGFR	Yes	15 (10.7)
	No	83 (59.3)
	N/A	42 (30.0)
PD-L1	Yes	40 (28.6)
	No	51 (36.4)
	N/A	49 (35.0)
ROS	Yes	2 (1.4)
	No	76 (54.3)
	N/A	62 (44.3)
Intent of treatment	Palliative	127 (90.7)
	Curative	2 (1.4)
	N/A	11 (7.9)

N/A, data not available.

Table S2 Descriptive analysis of chemotherapy and treatment

Variables	Description	N (%)
Chemotherapy	Yes	86 (61.4)
	No	54 (38.6)
Paclitaxel	Yes	5 (3.6)
	No	49 (35.0)
	N/A	86 (61.4)
Pemetrexed	Yes	53 (37.9)
	No	62 (44.3)
	N/A	25 (17.9)
Carboplatin	Yes	75 (53.6)
	No	41 (29.3)
	N/A	24 (17.1)
Cisplatin	Yes	15 (10.7)
	No	100 (71.4)
	N/A	25 (17.9)

N/A, data not available.

Table S3 Descriptive analysis of immunotherapy

Variables	Description	N (%)
Immunotherapy	Yes	35 (25.0)
	No	105 (75.0)
Pembrolizumab (KEYTRUDA)	Yes	30 (21.4)
	No	86 (61.4)
	N/A	24 (17.1)
Nivolumab	Yes	6 (4.3)
	No	111 (79.3)
Anti-ALK	N/A	23 (16.4)
	Yes	9 (6.4)
Crizotinib	No	131 (93.6)
	Yes	5 (3.6)
	No	48 (34.3)
Alectinib	N/A	87 (62.1)
	Yes	5 (3.6)
	No	108 (77.1)
Anti-EGFR	N/A	27 (19.3)
	Yes	7 (5.0)
	No	133 (95.0)
Erlotinib	N/A	0
	Yes	6 (4.3)
	No	49 (35.0)
	N/A	85 (60.7)

N/A, data not available.